Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to protect hearts after bypass surgery

NCT ID NCT07192211

Disease control Sponsor: Rohto Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called ADR-002K in 50 people with heart failure caused by blocked heart arteries who are scheduled for bypass surgery. The goal is to see if the drug can prevent heart-related events and improve heart function over two years. Participants must have a weak heart pump (less than 40% ejection fraction) and no recent heart attacks or severe valve disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients clinically diagnosed with chronic heart failure due to ischemic heart disease who undergo CABG 2. Patients with an LVEF of less than 40% as determined by the cardiac ultrasound at the screening examination. 3. Others Exclusion Criteria: 1. Patients who have a combination of cardiovascular disease such as severe organic valvular disease. 2. Patients who have developed acute coronary syndrome within 3 months prior to obtaining consent. 3. Others

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic heart failure due to ischemic heart disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic heart disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The University of Osaka Hospital

    RECRUITING

    Osaka, Suita, 5650871, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.